- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00815776
Treatment Outcomes for Temporomandibular Disorders (TMD) Via the Clayton Intra-aural Device (CID) Clinical Trial
August 16, 2010 updated by: Ascentia Health, Inc.
Treatment Outcome of Temporomandibular Disorders Via the Clayton Intra-aural Device (CID): A Randomized Clinical Trial
The purpose of this study is to characterize the safety profile and assess the effectiveness of the CID in treating subjects with temporomandibular disorders (TMDs).
This study is an open-label, three arm, randomized, unblinded clinical trial with a pre-treatment screening phase, a baseline visit and a 3 month treatment or exercise phase.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
After providing consent, subjects will be assessed as to whether they meet inclusion criteria for the study.
Subjects will complete a 4 week diary to measure TMD symptoms by recording pain levels on a Visual Analog Scale (VAS) twice daily.
Standardized Research Diagnostic Criteria (RDC) are used to classify types of TMDs.
The formal assessment tool is known as the RDC/TMD.
It is an empirically-based and operationalized system for diagnosing and classifying RDC/TMD using a biopsychosocial model of disease as a framework.
The CMI/TMD(hereafter referred to as the CMI) is designed to provide a basis for evaluating the severity of TMD signs and symptoms.
The CMI score is calculated from a dysfunction index (DI) and palpation index (PI).
The majority of questions found in the CMI are also included in the RDC/TMD, with the exception of five questions.
As part of the baseline medical history, all subjects will be asked the five questions that are included in the RDC/TMD but not included in the CMI.
Data from the CMI and the five RDC/TMD questions will be combined in the database and scored according to scoring guidelines for the RDC/TMD in order to diagnose and classify TMDs for all study subjects.
Subjects may be categorized in one or more of the three diagnostic groups, including muscle disorders (myofascial pain), arthralgia, and disc displacements with reduction.
Subjects will have an examination using the CMI at their screening visit.
Subjects who meet inclusion criteria will be randomized to one of three groups: The study device (Clayton Intra-aural Device (CID)) group, the mouth splint group, or the exercise group.
Subjects in all groups will return to the clinic for a baseline visit, followed by visits at one month, two months and three months post-baseline to return their completed 4 week VAS diary and to complete follow-up testing.
At the baseline visit, subjects will have a targeted physical examination, with results documented by the investigator on the CMI questionnaire.
Subjects will complete an in-office VAS score, a Modified SSI questionnaire, and will also complete the TMJ Scale, a questionnaire designed to measure possible improvement using a 10 point scale.
At each follow-up visit, each subject will complete questionnaires (including the Modified SSI questionnaire and an in-office VAS score)and will have a targeted physical examination, with results documented by the investigator on the CMI questionnaire.
At each follow-up visit, subjects will be issued a new monthly diary to complete for the VAS scores twice daily, (once in the morning before 10:00 a.m. and once before bed) as well as to track their device wearing time or exercise compliance, as applicable.
At the three month follow-up visit, subjects will also complete the TMJ Scale.
Adverse events will be assessed at each visit.
Study Type
Interventional
Enrollment (Actual)
152
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
D.f.
-
Mexico City, D.f., Mexico, 06700
- Instituto Mexicano de Investigación Clinica
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
A subject must meet all of the following criteria to be eligible for study participation:
- Subjects who present to IMIC for jaw pain or dysfunction
- Subjects who sign and date an IRB/EC approved informed consent form
Subjects must have an RDC/TMD diagnoses that include at least one of the following:
- Myofascial Pain
- Arthralgia
- Disc displacement with reduction; AND
The subject has the presence of one or more of the following findings associated with pain as demonstrated with a VAS score of >4:
- Increased (>60mm) or decreased (<40mm) range of interincisal jaw opening;
- Pain upon any jaw movement;
- Pain on digital palpation (about 0.45 kg of pressure) of the periauricular area or external auditory meatal areas;
- Pain on digital palpation (about 0.45 kg of pressure) in 2 or more muscles of mastication; or
- Joint sound with pain
Exclusion Criteria:
- Subjects diagnosed with rheumatoid arthritis, osteoarthritis, osteoarthrosis or another connective tissue disorder
- Subjects who have had direct trauma to the jaw
- Subjects who have used an occlusal appliance to treat a TMD within the previous six months
- Subjects who have had prior TMJ or ear surgery
- Subjects with any physical or behavioral disorder, which, in the opinion of the Principal Investigator, may interfere with the use of the device or compliance with the study protocol
- Subjects who have a narrow ear canal or impression of the ear canal, which is prolapsed due to an anatomical shift or failure of the ear canal wall structure, or a canal that does not allow for the ear canal second turn to be identified
- Subjects with visible or congenital ear deformity as observed on targeted physical exam
- Subjects whose ear canal anatomy does not allow for fit of the study device
- Subjects who have taken a narcotic pain medication in the last seven days or who have taken aspirin or a non-steroidal anti-inflammatory agent in the last 24 hours
- Subjects who have a history of ear pain unrelated to TMJ
- Subjects who have a history of ear drainage in the past 2 years
- Subjects who have active ear drainage, swelling, or redness as observed on targeted physical exam
- Subjects whom the investigator believes may not be a appropriate candidates for an intra-oral splint due to missing or poor quality dentition or untreated pain of dental origin (pulpal pain, pericoronitis of wisdom teeth, or similar conditions)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Treatment group receiving the CID
|
The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear.
Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear.
(For the purpose of this protocol, the pair of inserts will be referred to as the "CID").
|
Active Comparator: 2
Group assigned a mouth splint
|
Group 2 subjects will be assigned to the active control device, which is current standard of care therapy.
The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition.
The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model.
This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
|
Active Comparator: Exercise Control Group
Group who received no device but were instead assigned a study-specified jaw exercise program
|
Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries.
The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds.
Subjects will then close their jaw and rest 10 seconds.
The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch.
Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline In Craniomandibular Index (CMI) Scores At 3 Months (In A Scale)
Time Frame: Change from Baseline in Craniomandibular Index (CMI) Scores at 3 months (in a scale)
|
The Craniomandibular Index (CMI) is designed to provide a basis for evaluating the severity of Temporomandibular Disorder (TMD) signs and symptoms.
The assessment involves asking questions related to the condition of Mandibular Movement, TMJ noise, and palpations of the extraoral muscle, neck muscle, TMJ capsule and intraoral muscle.
The answers to all of the questions are combined to calculate a score from 0 to 1 in which 0 represents no TMD signs and symptoms and 1 represents the most severe TMD signs and symptoms.
|
Change from Baseline in Craniomandibular Index (CMI) Scores at 3 months (in a scale)
|
Number of Subjects With Adverse Events
Time Frame: From Baseline through 3 months post-baseline visit.
|
Subjects were assessed for adverse events from the baseline visit through study completion (3 months post-baseline).
Adverse events were categorized by the investigator for severity and relationship to treatment.
|
From Baseline through 3 months post-baseline visit.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline In Craniomandibular Index (CMI) Scores At 3 Months (In A Scale)
Time Frame: Change from Baseline in Craniomandibular Index (CMI) Score at Three Months Post-Baseline (in a scale)
|
The Craniomandibular Index (CMI) is designed to provide a basis for evaluating the severity of Temporomandibular Disorder (TMD) signs and symptoms.
The assessment involves asking questions related to the condition of Mandibular Movement, TMJ noise, and palpations of the extraoral muscle, neck muscle, TMJ capsule and intraoral muscle.
The answers to all of the questions are combined to calculate a score from 0 to 1 in which 0 represents no TMD signs and symptoms and 1 represents the most severe TMD signs and symptoms.
|
Change from Baseline in Craniomandibular Index (CMI) Score at Three Months Post-Baseline (in a scale)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Alejandro Tsuchiya, DDS, Insitituto Mexicano de Investigacion Clinica
- Study Director: Lawrence G. Clayton, M.A., Ascentia Health, Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2008
Primary Completion (Actual)
January 1, 2009
Study Completion (Actual)
January 1, 2009
Study Registration Dates
First Submitted
December 29, 2008
First Submitted That Met QC Criteria
December 29, 2008
First Posted (Estimate)
December 30, 2008
Study Record Updates
Last Update Posted (Estimate)
August 24, 2010
Last Update Submitted That Met QC Criteria
August 16, 2010
Last Verified
August 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CID2007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Temporomandibular Disorders
-
University of Nove de JulhoUnknownTemporomandibular DisorderBrazil
-
Hacettepe UniversityThe Scientific and Technological Research Council of TurkeyRecruitingTemporomandibular Joint Disorders | Temporomandibular Joint Dysfunction Syndrome | Temporomandibular Disorder | Temporomandibular Joint Pain | Manual Therapy | Temporomandibular Joint Disc DisplacementTurkey
-
Yeditepe UniversityUnknownTemporomandibular Disorders, Articular Disc Disorder (Reducing or Non-Reducing) | Osteopathy in Temporomandibular DisordersTurkey
-
University of ValenciaCompletedTemporomandibular Dysfunction (TMD)Spain
-
Beirut Arab UniversityRecruitingTemporomandibular DisorderLebanon
-
Riphah International UniversityRecruitingTemporomandibular DisorderPakistan
-
Hams Hamed AbdelrahmanCompletedTemporomandibular DisorderEgypt
-
Centre Hospitalier Universitaire de NiceCompleted
-
Federal University of Rio Grande do SulCompletedTemporomandibular Disorder
-
University of Nove de JulhoCompleted
Clinical Trials on Clayton Intra-aural Device (CID)
-
Federico II UniversityCompletedPain | Myofascial Pain | Temporomandibular Disorder | Psychosocial ImpairmentItaly
-
Future University in EgyptCompleted
-
Chang Gung Memorial HospitalDOTSPACERecruiting
-
Procter and GambleCompletedStress Urinary IncontinenceUnited States
-
Grand River HospitalNot yet recruiting
-
Glo Science, Inc.EEC Institute, Inc.CompletedPeriodontal Diseases | Tooth DiscolorationUnited States
-
LabrhaStatitecRecruitingSafety of Use and Efficacy of Pandora for Patients Suffering From Gonarthrosis (PANDORA2) (PANDORA2)Knee OsteoarthritisFrance, Monaco
-
Kitasato UniversityRecruitingAtherosclerosis | Acute Coronary Syndrome | Stable Angina | Coronary; Ischemic | STEMI - ST-segment Elevation Myocardial Infarction | NSTEMI - Non-ST-Segment Elevation Myocardial InfarctionJapan
-
Boston Scientific CorporationCompletedSafety Issues | Efficacy, SelfSpain, Italy, Denmark, United Kingdom
-
ReShape LifesciencesUnknown